Zacks Research Has Optimistic Outlook of ResMed Q2 Earnings

ResMed Inc. (NYSE:RMD) – Stock analysts at Zacks Research boosted their Q2 2025 earnings estimates for ResMed in a research note issued on Wednesday, January 29th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $2.27 for the quarter, up from their previous estimate of $2.26. The consensus estimate for ResMed’s current full-year earnings is $9.35 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.30 EPS, Q4 2025 earnings at $2.37 EPS, FY2025 earnings at $9.13 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.34 EPS, Q3 2026 earnings at $2.49 EPS, Q4 2026 earnings at $2.49 EPS, FY2026 earnings at $9.58 EPS, Q2 2027 earnings at $2.57 EPS and FY2027 earnings at $10.50 EPS.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 23.15% and a return on equity of 25.53%.

A number of other research analysts have also recently commented on RMD. KeyCorp raised their target price on ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Royal Bank of Canada raised their price objective on ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a research report on Friday, October 25th. Stifel Nicolaus initiated coverage on shares of ResMed in a research report on Friday, December 13th. They issued a “hold” rating and a $250.00 target price on the stock. Robert W. Baird lifted their price target on shares of ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Finally, The Goldman Sachs Group assumed coverage on shares of ResMed in a report on Thursday, January 16th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $238.40.

ResMed Stock Performance

Shares of RMD opened at $257.63 on Friday. ResMed has a one year low of $170.56 and a one year high of $263.05. The company has a 50-day simple moving average of $240.04 and a two-hundred day simple moving average of $235.84. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91. The firm has a market capitalization of $37.82 billion, a PE ratio of 34.12, a price-to-earnings-growth ratio of 1.83 and a beta of 0.70.

Insider Activity

In related news, Director Witte Jan De sold 796 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the transaction, the director now owns 6,723 shares of the company’s stock, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Justin Leong sold 6,160 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $243.09, for a total transaction of $1,497,434.40. Following the sale, the insider now directly owns 21,718 shares of the company’s stock, valued at approximately $5,279,428.62. This represents a 22.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,030 shares of company stock valued at $2,702,687 over the last three months. Insiders own 0.71% of the company’s stock.

Institutional Investors Weigh In On ResMed

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of ResMed by 10.9% during the 3rd quarter. Geode Capital Management LLC now owns 3,858,814 shares of the medical equipment provider’s stock valued at $939,114,000 after purchasing an additional 380,383 shares during the period. Caisse DE Depot ET Placement DU Quebec lifted its position in shares of ResMed by 726.3% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 283,801 shares of the medical equipment provider’s stock valued at $69,281,000 after acquiring an additional 249,454 shares in the last quarter. Nordea Investment Management AB grew its position in shares of ResMed by 92.7% during the fourth quarter. Nordea Investment Management AB now owns 448,151 shares of the medical equipment provider’s stock worth $103,214,000 after purchasing an additional 215,561 shares in the last quarter. State Street Corp lifted its holdings in ResMed by 1.9% in the 3rd quarter. State Street Corp now owns 6,261,633 shares of the medical equipment provider’s stock worth $1,528,590,000 after purchasing an additional 116,918 shares in the last quarter. Finally, AustralianSuper Pty Ltd boosted its stake in ResMed by 3,266.5% in the 4th quarter. AustralianSuper Pty Ltd now owns 103,923 shares of the medical equipment provider’s stock worth $23,766,000 after purchasing an additional 100,836 shares during the period. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.